Last reviewed · How we verify
Ademetionine 1
Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.
Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function. Used for Liver disease and cholestasis, Hepatic dysfunction, Drug-induced liver injury.
At a glance
| Generic name | Ademetionine 1 |
|---|---|
| Sponsor | Zhejiang Hisun Pharmaceutical Co. Ltd. |
| Drug class | Hepatoprotective agent / Methyl donor |
| Target | S-adenosylmethionine (SAM) pathway / cellular methylation |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Ademetionine (also known as S-adenosyl methionine or SAM) is an endogenous compound that serves as the primary methyl donor in cells. It participates in critical methylation reactions involving proteins, lipids, and nucleic acids, and supports hepatocyte membrane integrity and regeneration. By restoring depleted SAM levels, it enhances liver function and reduces cholestasis and hepatic damage.
Approved indications
- Liver disease and cholestasis
- Hepatic dysfunction
- Drug-induced liver injury
Common side effects
- Gastrointestinal disturbance
- Nausea
- Headache
Key clinical trials
- Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis (PHASE2)
- SAMe in Prevention of Oxaliplatin-associated Liver Injury (PHASE2)
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia (NA)
- Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM) (NA)
- SAMe Trial for Patients With Alcoholic Cirrhosis (PHASE2)
- Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly (NA)
- S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands (PHASE4)
- LAparoscopic Preventive PRErectal Mesh (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ademetionine 1 CI brief — competitive landscape report
- Ademetionine 1 updates RSS · CI watch RSS
- Zhejiang Hisun Pharmaceutical Co. Ltd. portfolio CI